Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786262 · ClinicalTrials.gov registry record · Phase 3
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 1 and Severe Hypoglycemia, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT04786262: Recruiting Phase 3 study of Diabetes Mellitus, Type 1 and Severe Hypoglycemia, sponsored by Vertex Pharmaceuticals Incorporated.
NCT04786262 is a Phase 3 study of Diabetes Mellitus, Type 1 and Severe Hypoglycemia that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 52 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04786262, a Phase 3 study of Diabetes Mellitus, Type 1 and Severe Hypoglycemia, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Conditions Studied
Interventions
- BIOLOGICAL VX-880
Study Locations (20)
Other
- University of Alberta, Edmonton - Edmonton
- McGill University Health Centre - Montreal
- Toronto General Hospital (TGH) - Toronto
- Vancouver General Hospital - Vancouver
- CHU Lille - Lille
- Centre de recherche en Biomédecine de Strasbourg - Strasbourg
- Dresden Center for Islet Transplantation - Dresden
- IRCCS Ospedale San Raffaele - Milan
California
- City of Hope - Duarte
- University of California San Francisco - San Francisco
Illinois
- Northwestern Organ Transplant Center - Chicago
- University of Chicago - Chicago
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center Montefiore - Pittsburgh
Florida
- UHealth Diabetes Research Institute - Miami
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Baylor Scott and White Research Institute - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 3 |
What NCT04786262 shows while recruiting
NCT04786262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which VX-880 is the first listed.
NCT04786262 names 20 study sites across 10 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04786262 about?
NCT04786262 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes". This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
What is the current status of trial NCT04786262?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2021-03-29. Estimated completion is 2030-06-30.
What conditions does trial NCT04786262 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Severe Hypoglycemia, Impaired Hypoglycemic Awareness.
What interventions are being tested in trial NCT04786262?
The interventions under investigation include: VX-880 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04786262?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04786262 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04786262's enrollment target sits among peer trials
52 68th of 118 higher than 50 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI